Clinical impact of occult hepatitis B virus infection in immunosuppressed patients - Wikidata - wikimedia - TriplyDB

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

http://www.wikidata.org/entity/Q27006996

about

Hepatitis B virus reactivation with a rituximab-containing regimen Occult hepatitis B virus infection Treatment of rheumatic diseases and hepatitis B virus coinfection Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance.Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.Natural history of chronic hepatitis B virus infection.Prevention of hepatitis B virus infection: from the past to the future.Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.Occult HBV infection in the oncohematological setting.Molecular diversity in irregular or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples.Occult hepatitis B virus infection: clinical implications in tuberculosis treatment.Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma.Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for Occult HBV Infection in HIV patients with negative HBsAg in Chile.Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis.The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc Testing Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients.Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.First report of occult hepatitis B infection among ART naïve HIV seropositive individuals in Maputo, Mozambique.Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management.

P2860

Q26785963-59069547-6FF9-449D-8EBB-4EE7CDB7AA22 Q27004224-9E6D4ECB-C8D3-42D1-BC9C-DC5402BFEA70 Q28084305-6342ED1B-CA0E-4045-A703-127C63869287 Q35127050-9F10ADE7-9194-47DD-A257-FC0399EF422F Q36294422-AABCEAF6-152D-4F0B-9FF5-8F1116FEAF1F Q38300425-23F90341-7296-4463-8AC6-189E04DC69C4 Q38354222-C47BBA9E-797B-4FFB-AD27-6F7ADD373B10 Q38408897-C964F4CD-FA1E-49CD-AD69-F031E19934B7 Q38807875-2B391BB9-3804-4627-B990-3A571589312A Q39224652-4E369A98-C1DC-41EC-BA30-C1F0B680BE47 Q39394078-C47D0E7D-4D56-4C73-ADE0-0D55A123ADDA Q40097433-F235ED9F-718E-45A0-B0A7-F1CBA957DB92 Q40528258-6F62AD59-0F05-43A6-9651-1D93E66F7E70 Q40595308-939EC0B2-78B8-40AF-A86A-CD63EA1E490E Q40727234-7FA96BFD-25F2-4E03-A1DF-3BE3ED13CA25 Q41111337-6D06E02A-4AE9-4BC9-99EC-060B25F83397 Q41925761-03651FB5-0842-4970-B71E-63AFA4AB9395 Q45326378-3F358C4D-E0ED-4636-B021-BA690A3EC40C Q47556031-9E432373-4DAE-4EB9-AC06-9E5FCE8BD091 Q52620441-B52E9943-8D43-44FB-91DF-C61BF5496D24

P2860

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

http://www.wikidata.org/entity/Q27006996

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@ast

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@en

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@nl

type

label

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@ast

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@en

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@nl

prefLabel

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@ast

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@en

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@nl

P1433

Q27006996-6E1B6AA4-1B77-414C-A162-1FC95D64A4AB

P1476

Q27006996-1C3BCA25-7F14-41CC-8557-8D898E209953

P2093

Q27006996-3365F1E7-035A-497F-B491-9C1D7A5A68DD

Q27006996-DABFD650-B52D-404C-9485-A0F632AE6DED

Q27006996-FA709A00-F13C-49EC-917A-478B9D71E84D

P2860

Q27006996-00FC5523-BD69-4B2E-8991-1A638F5E33C2

Q27006996-01124959-A43D-4AD9-A382-F6B6F6EF295E

Q27006996-03B83FDC-D7BA-4E3B-929C-A81264DCC49D

Q27006996-045955DB-84FE-4F8F-A960-308970464E88

Q27006996-04FA388B-21C4-4180-9574-8B7B4D700FF0

Q27006996-056B9A36-B959-40AF-A0F2-EE61C2EF9B71

Q27006996-08B4596A-6115-4761-8830-7B54FD7993B3

Q27006996-0B42965D-C380-4822-A117-A1EA94D77129

Q27006996-0F647CCA-54CC-4DA2-803A-7E99A2EABC41

Q27006996-16B8E2E2-ADE3-4CB4-88E6-BEAC64C570F1

P304

Q27006996-98D24154-D230-4519-801A-CE2FBE5F790B

P31

Q27006996-0D785FDE-3919-4C9D-9FD6-5A46890B13E4

P3181

Q27006996-E48FC548-5236-4235-B92D-E3DAC7755E6A

P356

Q27006996-B44DE65F-593A-49E2-A9F9-FCA88D49D444

P407

Q27006996-7DAEFA62-06E0-4E94-BCBE-428EB92247F0

P433

Q27006996-FA327E73-D053-42B4-B9FE-71B79A4EC604

P478

Q27006996-03BCF34B-0F15-4902-B9FC-297949617317

P50

Q27006996-5CB29766-B4EE-4E1A-A5D6-342DA3E3004B

Q27006996-BE70114E-D366-4F54-ACAE-7C79F55862D0

Q27006996-EFFEC5D1-7F4A-4532-8726-9F19A8BE3602

P577

Q27006996-D1153DF9-A5D1-4C04-B17F-1298892A8028

P5875

Q27006996-E992C20F-3151-4F5F-88A5-4C9F6B46EA0E

P698

Q27006996-1D32EE4F-B9A7-4B0A-BCD4-3710DB463762

P921

Q27006996-1DF9B5C9-A580-4C51-A8AC-ADA1AC59BAA7

Q27006996-97C5CBD4-1285-4875-B965-CC6BED6A4D6B

P932

Q27006996-61C727FE-84F8-4E80-B22A-E99CE98123C4

P3181

P356

P1433

World journal of hepatology

P1476

Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

@en

P2093

Caterina Sagnelli

http://www.w3.org/2001/XMLSchema#string

Evangelista Sagnelli

http://www.w3.org/2001/XMLSchema#string

Salvatore Martini

http://www.w3.org/2001/XMLSchema#string

P2860

Current trends in management of hepatitis B virus reactivation in the biologic therapy era

Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.

Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.

Chronic hepatitis B.

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease.

Occult hepatitis B virus infection and its clinical implications.

Occult hepatitis B.

Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV.

Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation.

P304

384-393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4690511

http://www.w3.org/2001/XMLSchema#string

P356

10.4254/WJH.V6.I6.384

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Pietro Filippini

Mariantonietta Pisaturo

P577

2014-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263896337

http://www.w3.org/2001/XMLSchema#string

P698

25018849

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

4081613

http://www.w3.org/2001/XMLSchema#string